<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Dev Immunol</journal-id><journal-title>Clinical and Developmental Immunology</journal-title><issn pub-type="ppub">1740-2522</issn><issn pub-type="epub">1740-2530</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15154607</article-id><article-id pub-id-type="pmc">2275406</article-id>
        <article-id pub-id-type="pii">S1740252204000034</article-id>
        <article-id pub-id-type="doi">10.1080/10446670410001670445</article-id>
    <article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Suppression of Leukotriene B<sub>4</sub> Generation by <italic>Ex-vivo</italic> Neutrophils Isolated from Asthma Patients on Dietary Supplementation with Gammalinolenic Acid-containing Borage Oil: Possible Implication in Asthma</article-title></title-group><contrib-group>
        <contrib contrib-type="author"><name><surname>Ziboh</surname><given-names>Vincent A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib>
        <contrib contrib-type="author"><name><surname>Naguwa</surname><given-names>Stanley</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib>
        <contrib contrib-type="author"><name><surname>Vang</surname><given-names>Kao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib>
        <contrib contrib-type="author"><name><surname>Wineinger</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib>
        <contrib contrib-type="author"><name><surname>Morrissey</surname><given-names> Brian M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib>
        <contrib contrib-type="author"><name><surname>McIntyre</surname><given-names>J. A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib>
        <contrib contrib-type="author"><name><surname>Watnik</surname><given-names>Mitchell</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib>
        <contrib contrib-type="author" corresp="yes"><name><surname>Gershwin</surname><given-names>M. Eric</given-names></name><address><email>megershwin@ucdavis.edu</email><phone>+1-530-752-2884</phone><fax>+1-530-752-4669</fax></address><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib>
    </contrib-group>
        <aff id="aff1"><label>1</label>
            <addr-line>Division of Rheumatology</addr-line>
            <addr-line>Allergy and Clinical Immunology</addr-line>
            <addr-line>Departments of Dermatology and Internal Medicine</addr-line>
            <addr-line>University of California at Davis School of Medicine, TB 192</addr-line>
            <addr-line>Davis</addr-line>
            <addr-line>CA</addr-line>
            <addr-line>95616</addr-line>
            <country>USA</country>
        </aff>
        <aff id="aff2"><label>2</label>
            <addr-line>Division of Pulmonary Medicine</addr-line>
            <addr-line>Department of Statistics</addr-line>
            <addr-line>University of California at Davis School of Medicine, TB 192</addr-line>
            <addr-line>Davis</addr-line>
            <addr-line>CA</addr-line>
            <addr-line>95616</addr-line>
            <country>USA</country>
        </aff>
        <aff id="aff3"><label>3</label>
            <addr-line>Division of Rheumatology</addr-line>
            <addr-line>Allergy and Clinical Immunology</addr-line>
            <addr-line>Departments of Dermatology and Internal Medicine</addr-line>
            <addr-line>University of California at Davis School of Medicine, TB 192</addr-line>
            <addr-line>Davis</addr-line>
            <addr-line>CA</addr-line>
            <addr-line>95616</addr-line>
            <country>USA</country>
        </aff>
    <pub-date pub-type="ppub"><month>3</month><year>2004</year></pub-date><volume>11</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &#x000a9; 2004 Hindawi Publishing Corporation.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
        <p>Dietary gammalinolenic acid (GLA), a potent inhibitor of 5-lipoxygenase (5-LOX) and suppressor of
leukotriene B<sub>4</sub> (LTB<sub>4</sub>), can attenuate the clinical course of rheumatoid arthritics, with negligible side
effects. Since Zileuton, also an inhibitor of 5-LOX, attenuates asthma but with an undesirable side
effect, we investigated whether dietary GLA would suppress biosynthesis of PMN-LTB<sub>4</sub> isolated from
asthma patients and attenuate asthma. Twenty-four mild-moderate asthma patients (16&#x02013;75 years) were
randomized to receive either 2.0 g daily GLA (borage oil) or corn oil (placebo) for 12 months. Blood
drawn at 3 months intervals was used to prepare sera for fatty acid analysis, PMNs for determining
phospholipid fatty acids and for LTB4 generation. Patients were monitored by daily asthma scores,
pulmonary function, and exhaled NO. Ingestion of daily GLA (i) increased DGLA (GLA metabolite) in
PMN-phospholipids; (ii) increased generation of PMN-15-HETrE (5-LOX metabolite of DGLA).
Increased PMN-DGLA/15-HETrE paralleled the decreased PMN generation of proinflammatory LTB<sub>4</sub>.
However, the suppression of PMN-LTB4 did not reveal statistically significant suppression of the
asthma scores evaluated. Nonetheless, the study demonstrated dietary fatty acid modulation of
endogenous inflammatory mediators without side effects and thus warrant further explorations into the
roles of GLA at higher doses, leukotrienes and asthma.</p>
    </abstract></article-meta></front></article>


